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ABSTRACT 
Conventional cardiovascular risk factors (CVRF) are accepted to identify asymptomatic 
individuals with high risk of acute myocardial infarction (AMI). However, AMI affects 
many patients previously classified at low risk. New biomarkers are needed to improve 
risk prediction. We propose to evaluate the NLRP3-inflammasome complex as a 
potential CVR indicator in healthy males and post-AMI patients and compare both 
groups by known CVRFs. We included 109 men with no history of cardiovascular 
disease (controls) and 150 AMI patients attending a cardiac rehabilitation program. 
AMI patients had higher mean of BMI and waist circumference than the controls. 
However, high percentages of the controls had a high BMI and a waist circumference 
>95 cm. The controls also had higher systolic blood pressure (P>0.001), total and LDL-
cholesterol, dietary nutrient and calorific intake. Fuster BEWAT Score (FBS) correlated 
more closely than Framingham risk score (FRS) with most CVRF, groups. However, 
only the FBS showed a correlation with inflammasome cytokine IL-1β. Several 
conventional CVRFs were significantly better in AMI patients; however, this group also 
had higher mRNA expression of the inflammasome gene NLRP3 and lower expression 
of the autophagy gene MAP-LC3. The controls had high levels of CVRF, probably 
reflecting unhealthy lifestyle. FBS reflects the efficiency of strategies to induce lifestyle 
changes such as cardiac rehabilitation programs, and could provide a sensitive 
evaluation cardiovascular risk. These results lead to the hypothesis that NLRP3-
inflammasome and associated IL-1β release have potential as CVR biomarkers, 
particularly in post-AMI patients with otherwise low risk scores. 
 
Key words: NLRP3-inflammasome complex, cardiovascular risk factors, Framingham 
Risk Score, Fuster BEWAT Score. 
 
  
 Page 3 of 32 
A
nt
io
xi
da
nt
s &
 R
ed
ox
 S
ig
na
lin
g
Co
ul
d 
N
LR
P3
-in
fla
m
m
as
om
e 
be
 a
 c
ar
di
ov
as
cu
la
r r
isk
 b
io
m
ar
ke
rs
 in
 A
cu
te
 M
yo
ca
rd
ia
l I
nf
ar
ct
io
n 
Pa
tie
nt
s?
 (d
oi:
 10
.10
89
/ar
s.2
01
6.6
97
0)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
4 
4 
 
A
n
ti
o
x
id
an
ts
 a
n
d
 R
ed
o
x
 S
ig
n
al
in
g
 
C
o
u
ld
 N
L
R
P
3
-i
n
fl
am
m
as
o
m
e 
b
e 
a 
ca
rd
io
v
as
cu
la
r 
ri
sk
 b
io
m
ar
k
er
s 
in
 A
cu
te
 M
y
o
ca
rd
ia
l 
In
fa
rc
ti
o
n
 P
at
ie
n
ts
?
 (
d
o
i:
 1
0
.1
0
8
9
/a
rs
.2
0
1
6
.6
9
7
0
) 
T
h
is
 p
ap
er
 h
as
 b
ee
n
 p
ee
r-
re
v
ie
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
li
ca
ti
o
n
, 
b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
g
o
 c
o
p
y
ed
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. 
T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death worldwide, with 
prevalence high in industrialized and low- and middle-income countries (2). Between 
1999 and 2004, only ~8% (1 in 12) of US adults had a low burden of cardiovascular risk 
factors, and similar levels of cardiovascular risk are reported in Spain (2). There is thus 
vast untapped potential for the prevention of atherosclerosis and CVD (3), prompting 
the promotion of lifestyle-modification strategies as a first-line approach. However, it is 
important to carefully evaluate how modifying specific parameters influences 
cardiovascular risk. 
Current guidelines identify 4 main primary risk factors for cardiovascular health 
(CVH): hypertension (blood pressure ≥140/90 or medication with blood-pressure-
lowering drugs), overweight or obesity (BMI ≥25), smoking, and physical inactivity 
(≤150 min/week) (3). However, a number of secondary risk factors also correlate 
closely with cardiovascular risk, such as waist circumference and diabetes mellitus, and 
there is moderate evidence for and influence of lipid profile (3). All of these risk factors 
are strongly influenced by diet, which like other lifestyle factors can be modified to 
either increase or reduce cardiovascular risk; for example, daily intake of fruit and 
vegetables lowers the risk of death from all causes, particularly CVD (3). Physical 
activity/exercise training, a healthy diet, weight loss, smoking cessation, and control of 
blood pressure (BP) and blood lipids and glucose are general strategies for cardiac 
rehabilitation programs. Based on these parameters (BP, exercise, weight, diet, and 
tobacco) the Fuster BEWAT Score (FBS) (2) has been designed as a tool for evaluating 
changes in healthy behaviors in relation to CVH.  
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Prominent among other possible cardiovascular risk indicators are markers of 
inflammation, and IL-1β in particular has been linked to several steps in the 
development of atherosclerosis, heart disease, and type II diabetes [Li]. The cytokines 
IL-1β and IL-18 are activated by the inflammasome complex, a multiprotein complex 
composed of an intracellular sensor, typically a Nod-like receptor (NLR), the precursor 
procaspase-1, and the adaptor ASC (apoptosis-associated speck-like protein containing 
a CARD) (5). 
In the present study, we compared cardiovascular risk factors and diet between 
men undergoing cardiac rehabilitation after acute myocardial infarction (AMI) and a 
control group of men with no history of CVD. The cardiovascular risk profile of both 
participant groups was assessed by Framingham 10 year risk score (FRS) and the FBS. 
RESULTS 
Anthropometric parameters are listed in Table 1. AMI patients had a higher mean BMI, 
(30.1±4.5 kg/m
2
) than the control group (28.2 ± 4.1 kg/m
2
), with a medium effect size 
(Cohen’s d, 0.48). Similarly, the AMI group had a higher mean waist circumference 
(107.1 ± 13.2 cm versus 102.6 ± 11.9 cm), with a low effect size (Cohen’s d, 0.35). 
However, a high percentage of the control group had a high BMI (overweight 48%, 
obesity 28.4%). Interestingly, the control group had higher systolic BP (144.8 ± 23.6 
mmHg versus 117.3 ± 16 mmHg) and diastolic BP (83.7 ± 11.7 mmHg versus 71.8 ± 9 
mmHg), with high effect sizes. This difference was reflected in 55% of control group 
members having systolic BP >140 mmHg, compared with 42% of the AMI group. 
Moreover, FRS-predicted CVR in the control group (13.5 ± 8.9%) was higher than in 
the AMI group (9.5 ± 6.9%). 
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Cardiovascular risk is linked to several biochemical parameters. No significant 
between-group differences were found for glucose, triglycerides, or VLDL-cholesterol. 
In contrast, levels of total cholesterol and LDL-cholesterol were higher in the control 
group (195.5 ± 36.6 mg/dL and 130.2 ± 34.5 mg/dL) than the AMI group (150.6 ± 42 
mg/dL and 88.4 ± 30.9 mg/dL), with a high effect size (Table 2). Control subjects also 
had higher levels of HDL-cholesterol (47.4 ± 13 mg/dL versus 40.2 ± 10.2 mg/dL), with 
a moderate effect size (Table 2). These differences translated into higher cardiovascular 
risk estimates for the control group, with 27% of control group members having total 
cholesterol >220 mg/dL, versus 4% for the AMI group; similarly, 30% of control group 
individuals had LDL-cholesterol >150md/dL, versus 3% of the AMI group. 
FBS was significantly higher in the AMI group than in the control group, both for 
overall score (AMI group, 8.73 ± 1.86 versus control group, 5.67 ± 2.64) and for 4 of 
the 5 individual score variables (Table 3). The control group had a higher score than the 
AMI group only for weight. Between-group differences were associated with high effect 
size for overall FBS and for 3 of the individual variables, whereas effect size was 
moderate for diet and weight (Table 3). 
Estimated dietary intake of calories and micronutrients is summarized in Table S1. The 
control group showed an overall higher intake than the AMI group. For example, intake 
of calories, lipids, and cholesterol was significantly higher in the control group, with 
differences generally associated with a moderate effect size, whereas higher estimated 
intake of saturated fats and carbohydrates in the control group was associated with a 
high effect size. The control group also had a higher estimated intake of protein, 
monounsaturated fat, and polyunsaturated fat, but with a low effect size. Between-group 
differences in the estimated intake of other mineral and vitamin nutrients were small 
and associated with a small effect size (Tables S2 and S3). The most notable difference 
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was sodium intake, which was higher in the control group (2734.8 ± 946.9 mg) than in 
the AMI group (2463.2 ± 1009.1 mg) (Table S2). 
The pathophysiology of coronary artery disease has been linked to lipid peroxidation 
and other indicators of oxidative stress, autophagy impairment, and inflammatory 
markers such as IL-1β (4-6). The AMI group showed higher levels of oxidative stress 
and IL-1β, with a high effect size (Table 2). Despite the more favorable values in the 
AMI group for several blood biochemical markers, likely due to the rehabilitation 
program, oxidative stress and inflammation levels remained high during the 
observational period of this study. Consistent with this, the AMI group showed higher 
levels of NLRP3 gene expression and lower levels of the autophagy-related gene MAP-
LC3 than the control group (Figure 1), suggesting an implication of both genes in the 
pathophysiology of coronary artery disease. 
The potential of FBS to predict cardiovascular risk status was evaluated by calculating 
Pearson’s correlation coefficient between total FBS and FRS. The 2 scores showed a 
significant negative correlation in both the control group and the AMI group (r= -0.364, 
P˂ 0.001 and r= -0.246, P˂ 0.005, respectively). The potential of the FBS and FRS to 
predict cardiovascular risk was assessed by calculating Pearson’s correlation coefficient 
for anthropometric and blood biochemical data from the control and AMI groups. 
Significantly negative correlations were observed between FBS and LDL-cholesterol 
(for the control group only), weight, BMI, all anthropometric measures, systolic and 
diastolic BP, and the inflammasome cytokine IL-1β. In almost all cases, correlations 
between FRS and anthropometric and blood biochemical parameters were less 
significant (Table 4). 
DISCUSSION 
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The goal of this study was to evaluate novel cardiac risk factors in men with no history 
of cardiovascular disease and others with a history of acute myocardial infarction. AMI 
is usually associated with unhealthy habits, and observational epidemiology data show 
an association between cardiovascular events and the risk factor burden, leading to an 
emphasis on risk assessment as the basis of measures to prevent the onset of coronary 
artery disease. Probably as a consequence of unhealthy lifestyles and poor nutritional 
habits among the general population, the control group shared several known risk 
factors with the AMI group. For example, there was no between-group difference in 
body weight; indeed, the control group had higher proportions of individuals with 
overweight and high numbers with a waist circumference >95 cm although the level of 
obesity was lower than in the AMI group. The control group also had higher average 
systolic BP and a higher percentage of individuals with systolic BP above 140 mmHg. 
However, this observation should be interpreted with caution because the AMI patients 
were receiving antihypertensive medication. Risk factors for systemic hypertension 
include obesity, excessive sodium intake, and alcohol consumption (9). An unhealthy 
diet accompanied by high sodium ingestion can increase BMI and hypertension, and 
restriction of daily sodium intake to 2400 mg is generally viewed as beneficial (9), with 
the American Heart Association recommending a daily intake of no more than 1500 mg. 
In the present study, the control group had a significantly higher sodium intake than the 
AMI group, possibly reflecting the effectiveness of dietary recommendations made to 
the AMI group as part of the cardiac rehabilitation program. Similarly, the control group 
had higher intakes of saturated fat and cholesterol. Limiting saturated fat intake is a 
standard feature of nutritional recommendations because excess dietary fat and calories 
can increase blood concentrations of LDL-cholesterol (3). The higher blood 
concentrations of total cholesterol and LDL-cholesterol in the control group likely 
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reflect the effectiveness of antilipid medication in the AMI group. Overall, estimated 
macronutrient consumption was higher in the control group. Within a fairly 
socioeconomically homogeneous population, our study thus identifies a clear tendency 
toward a hazardous intake of carbohydrates, proteins, and especially fat, associated with 
an elevated cardiovascular risk. This trend can be reversed by a greater focus on health 
promotion and cardiovascular disease prevention in the general population. To 
maximize their effectiveness, such interventions should begin in primary schools, with 
recommendations including moderate intake and better selection of macronutrients, 
adoption of low risk diets, and encouragement of healthy lifestyle habits. 
Dietary intake, BMI, waist circumference, blood lipid levels, and blood pressure are 
established indicators of cardiovascular risk. However, dietary intake is difficult to 
evaluate. Other habits demonstrated to improve CVH include regular physical exercise, 
smoking cessation, and regular consumption of fruit and vegetables (3,9). We evaluated 
cardiovascular risk in the study populations by the noninvasive Framingham and Fuster 
BEWAT scores. The FBS is easier to apply and is more easily understood by the 
general population (2). The control group had a higher mean FRS and a lower FBS 
(punctuation is inversely proportional to the risk) than the AMI group, which should be 
understood as a reduced CVH. Furthermore, FBS generally showed a more significant 
correlation than FRS with the principal cardiovascular risk factors: LDL-cholesterol, 
body weight, BMI and other anthropometric measures, and blood pressure. 
FBS also showed more significant correlation with the proinflammatory cytokine IL-1β, 
which is implicated in several CVDs (5). Inflammation has been proposed as 
cardiovascular risk factor, and high-sensitivity C-reactive protein (hsCRP) and IL-6 
have been proposed as important risk biomarkers (7). IL-1β is strongly implicated in 
CVD and monoclonal antibodies targeting IL-1β have shown cardioprotective potential 
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(5,7). IL-1β is one of two cytokines, together with IL-18, known to be activated by the 
inflammasome. The inflammasome is a protein complex composed of an intracellular 
sensor—typically a Nod-like receptor (NLR), the precursor procaspase-1, and the 
adaptor ASC. Inflammasome activation leads to the maturation of caspase-1 and the 
processing of its substrates, IL-1β and IL-18. The inflammasome has been implicated in 
CVD, and blockade of inflammasome-derived IL-1β has beneficial effects on cardiac 
function (5,7). The many factors implicated in inflammasome activation include high 
dietary levels of cholesterol, saturated fatty acid and obesity (5,7). The inclusion of 
obesity in FBS, along with a more quantitative compilation of other measures such as 
systolic blood pressure and smoking status (3) suggests that FBS could be a more 
accurate predictor of cardiovascular risk. Interestingly, despite the controlled diet of the 
AMI group, these participants had higher IL-1β concentrations than the control group, 
revealing a systemic inflammation that was not ameliorated by surgery and 
normalization of CVD biomarkers. The higher estimated intake of cholesterol and 
saturated fat among the control group participants anticipates a risk situation which 
could lead to inflammasome activation and associated IL-1β release. Consistent with the 
IL-1β data, the AMI group also showed increased gene expression of NLRP3.  
The NLRP3 inflammasome is inhibited by autophagy, a biological process involving 
lysosomes that preserves the balance between synthesis, degradation and recycling of 
cellular components and which is therefore essential for cell function and survival. This 
observation led to interest in the potential of autophagy-inducing treatments. The 
mechanisms by which autophagy regulates inflammasome activation are still unknown; 
however, it is well known that autophagy limits IL-1β production and release (6). 
Autophagy is an important mechanism in the maintenance of cardiac homeostasis, and 
accumulating evidence suggests that reduced autophagy is associated with heart failure 
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(6). In agreement with this, lower MAP-LC3 gene expression in the AMI group 
indicated reduced levels of autophagy, providing a possible explanation for the high 
levels of the NLRP3-inflammasome and IL-1β. Together these data show that the 
rehabilitation program did not improve inflammasome complex activation and thus did 
not fully reduce cardiovascular risk in AMI patients, in line with a previous report in 
which exercise did not reduce inflammatory markers after AMI. Furthermore, NLRP3 
expression predicts the severity of coronary atherosclerosis and inflammasome 
inhibition has been shown to improve post-AMI cardiac remodeling (1). Finally, our 
study supports the implication of the IL-1β by NLRP3-inflammasome complex 
activation as a preventive target. In this sense, the large scale Canakinumab Anti-
Inflammatory Thrombosis Outcomes Study (CANTOS) (8) will address to evaluate 
whether IL-1β inhibition with SC canakinumab every 3 months as compared to placebo 
can reduce recurrent cardiovascular event rates in stable coronary artery disease patients 
who remain at high inflammatory risk. Likewise, the inhibition of NLRP3 by MCC950 
a has been shown in a very recent study to reduces infarct size and preserves cardiac 
function, so the inhibition of an active inflammasome could be a therapeutic potential in 
AMI patients 
LIMITATIONS 
Despite the statistical significance of the results and the high number of patients and 
control participants, the study is limited by the small sample size. This limitation may 
be resolved in the future by the inclusion of patients and control participants from other 
centers. Furthermore, the control group is a representative population age-matched with 
the AMI group, and with similar socioeconomic status and a low percentage of 
unemployed individuals. The study did not include women because of the low incidence 
of CVD in women and in order to exclude gender-specific risk factors.  
 Page 11 of 32 
A
nt
io
xi
da
nt
s &
 R
ed
ox
 S
ig
na
lin
g
Co
ul
d 
N
LR
P3
-in
fla
m
m
as
om
e 
be
 a
 c
ar
di
ov
as
cu
la
r r
isk
 b
io
m
ar
ke
rs
 in
 A
cu
te
 M
yo
ca
rd
ia
l I
nf
ar
ct
io
n 
Pa
tie
nt
s?
 (d
oi:
 10
.10
89
/ar
s.2
01
6.6
97
0)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
12 
12 
 
A
n
ti
o
x
id
an
ts
 a
n
d
 R
ed
o
x
 S
ig
n
al
in
g
 
C
o
u
ld
 N
L
R
P
3
-i
n
fl
am
m
as
o
m
e 
b
e 
a 
ca
rd
io
v
as
cu
la
r 
ri
sk
 b
io
m
ar
k
er
s 
in
 A
cu
te
 M
y
o
ca
rd
ia
l 
In
fa
rc
ti
o
n
 P
at
ie
n
ts
?
 (
d
o
i:
 1
0
.1
0
8
9
/a
rs
.2
0
1
6
.6
9
7
0
) 
T
h
is
 p
ap
er
 h
as
 b
ee
n
 p
ee
r-
re
v
ie
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
li
ca
ti
o
n
, 
b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
g
o
 c
o
p
y
ed
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. 
T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
CONCLUSION 
Our study demonstrates the presence of a high number of cardiovascular risk factors in 
the general asymptomatic population, probably the result of an unhealthy lifestyle. The 
study results corroborate the usefulness of the FBS for the evaluation of cardiovascular 
risk without invasive measurements, and indicate that this score could reflect the 
efficiency of strategies aimed at inducing lifestyle changes, such as cardiac 
rehabilitation programs. The study also shows how the FBS correlates with traditional 
risk factors and implicates the inflammasome as a valuable biomarker of CVD risk in 
post-AMI patients with low scores on traditional risk measures. Our results further 
suggest a molecular basis for this association and indicate that the inflammasome is a 
potential therapeutic target for the prevention of CVD. 
INNOVATION 
Inflammasome has been indicated as being in the pathophysiology of CVDs and 
metabolic diseases with a high cardiovascular component such as obesity and type II 
diabetes and it has been suggested that oxidative stress and autophagy impairment could 
be among the factor responsible for NLRP3-inflammasome activation. This is an 
interesting issue that warrants consideration to design new experiments in order to gain 
further insight into its potential therapeutic applications, given that inflammasome 
activation is a modifiable factor. The results described in this article may serve as a new 
way to AMI patient management and a biomarker to predict the risk repetition. 
Furthermore, non-healthy life style can to induce a NLRP3-inflammasome dependent 
cardiovascular risk factor. 
Notes 
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Study participants: The control group consisted of 109 men older than 35 years with 
no history of cardiovascular disease. All control participants were recruited from among 
the staff at the University of Seville and their families. The control group was compared 
with 150 male patients who had previously suffered a heart attack and were attending 
the Virgen Macarena University Hospital, Seville, Spain (AMI group). All AMI group 
participants were included on a cardiac rehabilitation program run according to 
Sociedad Española de Cardiología recommendations. The rehabilitation program 
consisting of 1) physical training, 2) psychological support, and 3) control of risk 
factors, including help with lifestyle choices, diet, BP control, stopping smoking, and 
dyslipidemia. The study protocol and procedures were previously approved by the 
Seville University Ethics Committee and all participants gave written informed consent. 
Outcome measures 
Patients were assigned to the AMI group 6 months after AMI. The primary outcome 
measure was the FRS, calculated as the summation of all Framingham risk-related 
factors: age, sex, LDL-C or total cholesterol, HDL-C, BP, and smoking status. We also 
calculated the mean difference in FBS between the control and AMI groups to monitor 
progress toward health in the AMI patients (2). The FBS categorizes the 5 individual 
variables (BP, exercise, body weight, alimentation, and tobacco smoking) on a 15-point 
simple ordinal scale to evaluate healthy habits and non-laboratory-based CVH factors. 
For each participant, each variable is graded (0, 1, 2, or 3) according to its 
approximation to international guidelines for cardiovascular risks and habits, with 3 
being the optimal value (2).  
General and anthropometric data: For all participants, data collected included age, 
height, weight, body mass index, abdominal waist circumference, hip circumference, 
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wrist circumference, elbow circumference, bicipital fold, tricipital fold, subescapular 
fold, supraliac fold, BP, and pulse. Smoking status was recorded as smoker or non-
smoker. 
Biochemical parameters: Serum levels of glucose, total cholesterol, triglycerides, HDL, 
LDL, and VLDL were assayed by routine analytical methods. 
IL-1β: Serum levels of IL-1β were assayed in duplicate using commercial ELISA kits 
(Biosource). 
Lipid peroxidation: Lipid peroxidation in mononuclear blood cells was estimated from 
the accumulation of lipoperoxides using a commercial kit (Cayman Chemical, Ann 
Arbor, Michigan, USA). Thiobarbituric acid reactive substances (TBARS) were 
assessed from the levels of malondialdehyde (nmol malondialdehyde/mg protein). 
Real-time quantitative PCR (qPCR): The expression of the NLRP3 and MAP-LC3 
genes was analyzed by SYBR Green qPCR of mRNA extracted from blood 
mononuclear cells. Total cellular RNA was purified from the cells by the Trisure 
method (Bioline, London, UK). RNA concentration was determined 
spectrophotometrically. Contaminating genomic DNA was eliminated by incubation of 
1 g of total RNA from each sample with gDNA wipeout buffer for 5 min at 42 °C 
(Quantitect Reverse Transcription Kit, Qiagen, Hilden, Germany). RNA samples were 
subsequently reverse transcribed to cDNA using the QuantiTect Reverse Transcription 
Kit (Qiagen, Hilden, Germany). PCR amplifications were conducted with primers 
targeting NLRP3 (NM_004895.4), MAPLC3 (NM_022818), and beta-actin, used as an 
internal control. Thermal cycling conditions used were denaturation at 95 °C for 20 s, 
40 cycles of priming at 54 °C for 20 s, and elongation at 72 °C for 20 s. All reactions 
were performed in duplicate, and reaction mixes without RNA were used as negative 
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controls in each run. Absence of contaminating genomic DNA was confirmed by setting 
up control reactions with RNA that had not been reverse transcribed. Fold changes in 
the expression of genes of interest were calculated using the ΔΔCt method. 
Dietary assessment: Dietary intake was monitored over a 1-week period in which all 
food intakes was weighed and details of all meals recorded. In particular, three 
recollection days were registered at the day of recruitment by a dietitian. Another four 
days (including one weekend day) were registered by the patient, starting on the first 
day after incorporation in the study, with further supervision by the dietitian. Dietary 
content of macronutrients and selected micronutrients was calculated using the 
computer program Nutriber® and the Spain Food Composition Table. 
Statistical analysis 
Statistical analyses were performed with SPSS 23 and G * Power 3.1.9.2. Statistical 
significance of differences was assigned at p < 0.05 and statistical power at 1-β=0.80. 
Samples and outcome variables were assessed by the use of descriptive statistical 
variables such as frequency analysis, minimum and maximum values, means, and 
standard deviations. Pairwise between-group comparisons were made by Student’s t-test 
for normally distributed data and the Mann-Whitney U test for non-normally distributed 
data; normality was assessed with the Kolmogorov-Smirnov test. For the Student´s t-
test, the homoscedasticity assumption was evaluated by Levene’s test after the Lilliefors 
correction. Differences between the mean outcome variable scores in the AMI and 
control groups were assessed by post hoc analysis of the family of t-tests, including the 
t-test for independent samples and the Mann-Whitney U test, in G * Power 3.1.9.2. The 
following parameters for each outcome variable were introduced in the analysis: two 
tailed, normal distribution, probability alpha of 0.05, control group size, AMI group 
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size, control group mean value, and AMI group mean value. To adjust for the different 
sizes of the control and AMI groups, common standard deviation was calculated using 
the following formula, where n is sample size and s is the standard deviation: 
        √
        
          
 
       
 
This analysis provides Cohen's d as a measure of effect size. Values of 0.2, 0.5 and 0.8 
respectively indicate small, medium, and large effect sizes. Correlation between results 
was assessed by calculating Pearson’s correlation coefficient. 
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NLR: Nod-like receptor   
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Figure legend 
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Figure 1. Gene expression profiles in blood mononuclear cells (BMC) from AMI 
patients and the control group. Quantitative PCR determination of the relative gene 
expression of NLRP3 (A) and MAP-LC3 (B). Data are means±SD of 3 independent 
experiments. *P < 0.001 between patients and controls. 
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Tables 
Table 1. Anthropometrical parameters in male control participants and AMI 
patients. 
 Control group 
N=109 
AMI group 
N=150 
U/t* p Cohen´s d 
Age, years  52.5 (11.8) 56.1 (10.2) - - - 
30-40 16.5% 10.6% - - - 
41-50 23.8% 20% - - - 
51-60 32.1% 38% - - - 
61-70 20.2% 22% - - - 
≥70 8% 9.3% - - - 
Educational level      
Low 7.1% 8.1% - - - 
Medium 51.3% 48.4% - - - 
High 41.6% 43.5% - - - 
Background 
hypertension 
35% 55% - - - 
Treatment 
hypertension 
31% 41.3% - - - 
Treatment 
hypercholesterolemia 
7.5% 25.8% - - - 
Smokers 71% 85%  -  - - 
Height, cm 174.5 (6.8) 168.9 (6.4) 4341 0.000 0.84 
Weight, kg 85.9 (14.3) 86.1 (14.1) 7755 0.637 0.01 
BMI, kg/m
2
 28.2 (4.1) 30.1 (4.5) 5632 0.000 0.48 
Overweight, BMI 
25.0–29.9 kg/m2 
48% 40%  -  - - 
Obesity BMI 30 kg/m
2
 28.4% 50%  -  - - 
Waist circumference, 
cm 
102.6 (11.9) 107.1 (13.2) 6344 0.006 0.35 
>95 cm waist 
circumference 
77.4% 86%  -  - - 
Hip circumference, 
cm 
105.6 (8.1) 106.9 (8.2) 7079 0.136 0.16 
Wrist circumference, 
cm 
17.7 (1.8) 17.6 (1.2) 7529 0.470 0.10 
Elbow 
circumference, cm 
27.4 (2.2) 27.2 (2.3) 7678 0.642 0.06 
Bicipital fold, mm 12.3 (10.1) 11.2 (5) 7875 0.898 0.15 
Tricipital fold, mm 13.4 (5.9) 12.3 (5.8) 7623 0.575 0.06 
Subescapular fold, 
mm 
23.6 (8) 25.3 (7.5) -1.699* 0.09 0.22 
Supraliac fold, mm 21.5 (7.5) 19.4 (7.1) 6651 0.026 0.28 
Systolic blood 
pressure, mmHg 
144.8 (23.6) 117.3 (16) 2245 0.000 1.49 
Systolic blood 
pressure, >140 mmHg 
55% 42%  -  - - 
Diastolic blood 
pressure, mmHg 
83.7 (11.7) 71.8 (9) 2869 0.000 1.53 
Pulse 65.7 (9.5) 75.2 (13.4) 3782 0.000 0.77 
FRS, % 13.5 (8.9) 9.5 (6.9) 4237 0.001 0.39 
>20% 18.6% 12.4% - - - 
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Values are expressed as mean  (S.D.) or %. BMI, body mass index. U, Mann–Whitney U test; 
t= Student´s t test; p= p values; d, Cohen´s d. 
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Tables 
 
Table 2. Biochemical parameters in male control participants and AMI patients. 
 Recommen
ded 
value 
Control group 
(N=109) 
AMI group 
(N= 150) 
U/t* p Cohen´s d 
Glucose, 
mg/dL 
70-100 106.3 (21.7) 114.6 (49.4) 6443 0.238 0.21 
Glucose, (>100 
mg/dL) 
 47% 57% - - - 
Total 
Cholesterol, 
mg/dL 
150-220 195.5 (36.6) 150.6 (42) 8.894* 0.000 1.12 
Cholesterol, 
(>220 mg/dL) 
 27% 4% - - - 
Triglycerides, 
mg/dL 
70-170 143.8 (90.3) 135.4 (115.6) 7329 0.188 0.17 
HDL, mg/dL >35 47.4 (13) 40.2 (10.2) 3980 0.000 0.63 
LDL, mg/dL <150 130.2 (34.5) 88.4 (30.9) 2234 0.000 1.28 
LDL,  (>150 
mg/dL) 
 30% 3% - - - 
VLDL, mg/dL 5-40 28.1 (19.5) 24.7 (11.3) 4865 0.656 0.21 
Lipid 
peroxidation, 
nmol/mg 
 26.9 (46.2) 110.9 (108) 3848 0.000 0.95 
IL-1β, pg/mL  33.8 (34.3) 105.3 (67.3) 3085 0.000 1.26 
Values are expressed as mean (S.D.) or %. IL-1β, Interleukin 1β; HDL, high density 
lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; U, Mann–
Whitney U test; t, Student´s t test; p, p value; d, Cohen´s d. 
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Tables 
Table 3: FBS in male control participants and AMI patients. 
 Score 
range 
Control group 
(N= 109) 
AMI group 
(N= 150) 
U p d 
FBS 0-15 5.67 (2.64) 8.73 (1.86) 2491 0.000 1.50 
Blood 
pressure 
0-3 0.78 (1.01) 1.99 (1.06) 3257 0.000 1.15 
Exercise 0-3 1.05 (0.9) 1.77 (0.44) 4019 0.000 1.10 
Weight 0-3 1.15 (1.04) 0.71 (0.89) 5843 0.000 0.46 
Alimentation 0-3 1.35 (0.79) 1.75 (0.76) 5866 0.000 0.51 
Tobacco 0-3 1.46 (0.95) 2.51 (0.5) 3184 0.000 1.45 
Values are expressed as mean (S.D.). FBS, Fuster BEWAT Score; U, Mann–Whitney U test; t, 
Student´s t test; p, p values; d, Cohen´s d statistic. 
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Tables 
 
Table 4. Relationship between FBS/FRS and anthropometric/biochemical 
parameters in male control participants and AMI patient (Pearson correlation 
coefficient). 
 FBS Control FBS AMI FRS Control FRS AMI 
Glucose -0.004 -0.122 0.169 0.285** 
Total 
Cholesterol 
-0.137 -0.071 0.157 0.238* 
Triglycerides -0.145 -0.083 0.202 0.118 
HDL 0.180 0.109 -0.209* -0.178 
LDL -0.209* -0.055 0.286* 0.246** 
VLDL  -0.118 -0.084 0.181 0.234* 
Lipid 
peroxidation  
-0.100 0.105 0.001 0.013 
IL-1β  -0.280** -0.277* -0.010 0.049 
Height -0.007 0.045 -0.095 -0.324 
Weight -0.544*** -0.451*** 0.118 -0.198* 
BMI -0.618*** -0.531*** 0.241* -0.031 
Waist 
circumference 
-0.613*** -0.364*** 0.319** 0.151 
Hip 
circumference  
-0.494*** -0.434*** 0.196 0.005 
Wrist 
circumference  
-0.253** -0.215* 0.014 -0.078 
Elbow 
circumference  
-0.269** -0.319*** -0.162 -0.204* 
Bicipital fold  -0.334*** -0.324*** 0.032 -0.104 
Tricipital fold  -0.284** -0.222* 0.076 -0.211* 
Subescapular 
fold  
-0.545*** -0.431*** 0.110 -0.081 
Supraliac fold  -0.266* -0.296*** 0.090 -0.030 
Systolic 
blood 
pressure  
-0.397*** -0.491*** 0.60*** 0.378*** 
Diastolic 
blood 
pressure 
-0.287* -0.271** 0.379*** -0.011 
Pulse -0.081 0.119 0.072 -0.078 
*P˂0.05, ** P˂0.005, ***P˂0.001. FBS, Fuster BEWAT Score; FRS, Framingham Risk 
Score 
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Supplementary data 
Table 1. Estimated daily energy and macronutrients intakes in male control 
participants and AMI patients. 
 Control group 
(N= 109) 
AMI group 
(N= 150) 
U/t* p Cohen´s d 
Energy, kcal/d 2464.3 (483.4) 2181.7 (386.4) 4.963* .000 .67 
Protein,g/d 110.2 (24.5) 104.1 (35.2) 5259 .007 .22 
Lipids, g/d 105.7 (24.3) 90.3 (21.5) 4249 .000 .68 
SFA, g/d 26.1 (8.6) 19.3 (4.3) 3534 .000 .92 
MUFA, g/d 49.1 (12.2) 44.9 (11.7) 2.615* .009 .35 
PUFA, g/d 14.2 (5.2) 12.2 (4.9) 4987 .001 .37 
Cholesterol, g/d 352.4 (122.2) 275.8 (104.2) 4198 .000 .69 
Carbohydrates, g/d 312.3 (51.4) 235.9 (44.4) 1600 .000 1.62 
Fiber, g/d 25.5 (6.8) 25.4 (7.3) .099* .921 .01 
Values are expressed as mean (S.D.). FSA, saturated fat; MUFA, monounsaturated fat; PUFA, 
polyunsaturated fat U, Mann–Whitney U test; t, Student´s t test; p, p values; d, Cohen´s d. 
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Table 2. Estimated daily minerals intakes in male control participants and AMI 
patients. 
 Control group 
(N= 109) 
AMI group 
(N= 150) 
U/t* p Cohen´s d 
Na, mg/d 2734.8 (946.9) 2463.2 (1009.1) 5382 .013 .27 
K, mg/d 3842.7 (960.7) 3746.1 (927.1) .764* .445 .10 
Ca, mg/d 1119.2 (378.2) 1050.4 (420.3) 5765 .081 .17 
Mg, mg/d 374.8 (98.5) 369.5 (81.6) .425* .672 .06 
P, mg/d 1631.9 (401.1) 1628.2 (397.8) 6650 .965 .00 
Fe, mg/d 27.5 (16.1) 23.6 (15.5) 5130 .003 .24 
Cu, mg/d 4 (4.1) 6.1 (5.5) 5209 .005 .41 
Zn, mg/d 16.3 (11.9) 12 (9) 4668 .000 .42 
Cl, mg/d 2585.5 (1228.9) 2341.5 (1214.4) 5691 .509 .20 
Mn, mg/d 19.5 (30.4) 13 (16) 6285 .457 .29 
Se, µg/d 98.3 (34.1) 94.9 (28.7) 6219 .383 .10 
I, µg/d 164.3 (127.6) 153.5 (142.2) .582 .561 .07 
Values are expressed as mean (S.D.). U, Mann–Whitney U test; t, Student´s t test; p, p values; 
d, Cohen´s d. 
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Table 3. Estimated daily vitamins intakes in male control participants and AMI 
patients. 
 Control group 
(N= 109) 
AMI group 
(N= 150) 
U/t* p Cohen´s d 
Thiamine, mg/d 2.5 (3.2) 1.9 (1.4) 5729 .07 .26 
Riboflavin, mg/d 2 (0.6) 1.9 (0.7) 6194 .357 .11 
Pyridoxine, mg/d 2.5 (0.6) 2.4 (0.9) 6038 .222 .04 
Cyanocobalamin, 
µg/d 
10.5 (8.2) 9.4 (8.5) 5922 .149 .12 
Folate, µg/d 383.5 (133.7) 383.5 (136) 6540 .799 .00 
Niacin, mg/d 36.1 (23.7) 30.7 (9.2) 5615 .042 .34 
Ascorbic Acid, mg/d 189 (94.5) 195.7 (94.7) 6428 .638 .07 
Pantothenic acid, 
mg/d 
5.4 (1.5) 5.1 (1.4) 1,158* .130 .20 
Biotin, mg/d 9.3 (5.7) 10.8 (6.5) 5784 .088 .25 
Retinol, µg/d 1096.5 (796.9) 976.2 (515.8) 6451 .671 .19 
Cholecalciferol, µg/d 8 (6) 8.5 (9.6) 6477 .707 .07 
Tocopherol, mg/d 15.2 (5.5) 14.1 (6.3) 5670 .054 .18 
Values are expressed as mean (S.D.). U, Mann–Whitney U test; t, Student´s t test; p, p values; 
d, Cohen´s d. 
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Figure 1. Gene expression profiles in blood mononuclear cells (BMC) from AMI 
patients and the control group. Quantitative PCR determination of the relative gene 
expression of NLRP3 (A) and MAP-LC3 (B). Data are means±SD of 3 independent 
experiments. *P < 0.001 between patients and controls. 
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